News RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.1 ^USD	+3.85%		+1.89%	-67.40%

Apr. 09	RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	CI
Mar. 27	JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	Apr. 09	GL
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	Apr. 09	AQ
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	Apr. 09	CI
JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	Mar. 27	MT
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index	Mar. 17	CI
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	Mar. 11	PR
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 07	GL
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 07	AQ
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	Mar. 05	GL
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	Mar. 05	AQ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	Mar. 03	PR
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Feb. 26	BU
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
RAPT Therapeutics Shares Decline Following UBS Downgrade	Feb. 22	MT
UBS Downgrades RAPT Therapeutics to Neutral From Buy, Adjusts Price Target to $10 From $61	Feb. 22	MT
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
Barclays Adjusts Price Target on RAPT Therapeutics to $13 From $35, Maintains Overweight Rating	Feb. 21	MT
Leerink Partners Downgrades RAPT Therapeutics to Market Perform From Outperform, Price Target is $10	Feb. 21	MT
HC Wainwright Downgrades RAPT Therapeutics to Neutral From Buy	Feb. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Summary

Filters